• Something wrong with this record ?

Factors Influencing the Risk of Major Amputation in Patients with Diabetic Foot Ulcers Treated by Autologous Cell Therapy

J. Husakova, R. Bem, V. Fejfarova, A. Jirkovska, V. Woskova, R. Jarosikova, V. Lovasova, EB. Jude, M. Dubsky

. 2022 ; 2022 (-) : 3954740. [pub] 20220411

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22018816

Introduction: Autologous cell therapy (ACT) is one of the last options for limb salvage in patients with chronic limb-threatening ischemia (CLTI) and diabetic foot ulcers (DFU). However, some patients may still undergo a major amputation even after ACT, but the risk factors for this are not known. Therefore, the aim of our study was to assess the risk factors for major amputation in patients with CLTI and DFU during a 2-year follow-up after ACT. Methods: One hundred and thirteen patients after ACT were included in our study and divided into two groups: Group 1 with major amputation (AMP; n = 37) and Group 2 without amputation (nAMP, n = 76). The risk factors for major amputation were evaluated before ACT and included factors relating to the patient, the DFU, and the cell product. Results: The AMP group had significantly higher C-reactive protein (CRP) levels compared to the nAMP group (22.7 vs. 10.7 mg/L, p = 0.024). In stepwise logistic regression, independent predictors for major amputation were mutation of the gene for methylenetetrahydrofolate reductase (MTHFR) with heterozygote and homozygote polymorphism 1298 (OR 4.33 [95% CI 1.05-17.6]), smoking (OR 3.83 [95% CI 1.18-12.5]), and CRP > 10 mg/L (OR 2.76 [95% CI 0.93-8.21]). Lower transcutaneous oxygen pressure (TcPO2) values were observed in AMP patients compared to the nAMP group at one month (24.5 vs. 33.2, p = 0.012) and at 3 months (31.1 vs. 40.9, p = 0.009) after ACT. Conclusion: Our study showed that the risk for major amputation after ACT in patients with CLTI and DFU is increased by the presence of MTHFR heterozygote and homozygote gene mutations, smoking, and higher CRP at baseline. Lower TcPO2 at one and 3 months after ACT may also have a predictive value. Therefore, it is necessary to stop smoking before ACT, treat any infection, and, above all, consider antiaggregation or anticoagulant treatment after the procedure.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018816
003      
CZ-PrNML
005      
20220804135120.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2022/3954740 $2 doi
035    __
$a (PubMed)35450383
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Husakova, J $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/000000026073655X
245    10
$a Factors Influencing the Risk of Major Amputation in Patients with Diabetic Foot Ulcers Treated by Autologous Cell Therapy / $c J. Husakova, R. Bem, V. Fejfarova, A. Jirkovska, V. Woskova, R. Jarosikova, V. Lovasova, EB. Jude, M. Dubsky
520    9_
$a Introduction: Autologous cell therapy (ACT) is one of the last options for limb salvage in patients with chronic limb-threatening ischemia (CLTI) and diabetic foot ulcers (DFU). However, some patients may still undergo a major amputation even after ACT, but the risk factors for this are not known. Therefore, the aim of our study was to assess the risk factors for major amputation in patients with CLTI and DFU during a 2-year follow-up after ACT. Methods: One hundred and thirteen patients after ACT were included in our study and divided into two groups: Group 1 with major amputation (AMP; n = 37) and Group 2 without amputation (nAMP, n = 76). The risk factors for major amputation were evaluated before ACT and included factors relating to the patient, the DFU, and the cell product. Results: The AMP group had significantly higher C-reactive protein (CRP) levels compared to the nAMP group (22.7 vs. 10.7 mg/L, p = 0.024). In stepwise logistic regression, independent predictors for major amputation were mutation of the gene for methylenetetrahydrofolate reductase (MTHFR) with heterozygote and homozygote polymorphism 1298 (OR 4.33 [95% CI 1.05-17.6]), smoking (OR 3.83 [95% CI 1.18-12.5]), and CRP > 10 mg/L (OR 2.76 [95% CI 0.93-8.21]). Lower transcutaneous oxygen pressure (TcPO2) values were observed in AMP patients compared to the nAMP group at one month (24.5 vs. 33.2, p = 0.012) and at 3 months (31.1 vs. 40.9, p = 0.009) after ACT. Conclusion: Our study showed that the risk for major amputation after ACT in patients with CLTI and DFU is increased by the presence of MTHFR heterozygote and homozygote gene mutations, smoking, and higher CRP at baseline. Lower TcPO2 at one and 3 months after ACT may also have a predictive value. Therefore, it is necessary to stop smoking before ACT, treat any infection, and, above all, consider antiaggregation or anticoagulant treatment after the procedure.
650    _2
$a adenosinmonofosfát $7 D000249
650    _2
$a amputace $7 D000671
650    _2
$a buněčná a tkáňová terapie $7 D064987
650    _2
$a chronická kritická ischemie končetin $7 D000089802
650    12
$a diabetes mellitus $7 D003920
650    12
$a diabetická noha $x chirurgie $7 D017719
650    _2
$a lidé $7 D006801
650    _2
$a ischemie $x chirurgie $7 D007511
650    _2
$a záchrana končetiny $7 D023821
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
650    _2
$a výsledek terapie $7 D016896
650    _2
$a hojení ran $7 D014945
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bem, R $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $1 https://orcid.org/0000000341271846 $7 xx0104859
700    1_
$a Fejfarova, V $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic $u Second Faculty of Medicine, Charles Unviersity, Prague, Czech Republic $1 https://orcid.org/0000000344865383 $7 xx0074208
700    1_
$a Jirkovska, A $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $1 https://orcid.org/000000023622997X
700    1_
$a Woskova, V $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Jarosikova, R $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Lovasova, V $u First Faculty of Medicine, Charles University, Prague, Czech Republic $u Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $1 https://orcid.org/0000000326597725
700    1_
$a Jude, E B $u Diabetes Center, Tameside and Glossop Integrated Care NHS Foundation Trust and University of Manchester, Lancashire, UK $1 https://orcid.org/0000000231864122
700    1_
$a Dubsky, M $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000220780177 $7 xx0105570
773    0_
$w MED00181720 $t Journal of diabetes research $x 2314-6753 $g Roč. 2022, č. - (2022), s. 3954740
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35450383 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135113 $b ABA008
999    __
$a ok $b bmc $g 1822424 $s 1170059
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 2022 $c - $d 3954740 $e 20220411 $i 2314-6753 $m Journal of diabetes research $n J Diabetes Res $x MED00181720
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options